Scheelevägen 22
Lund 223 63
Sweden
46 46 19 20 00
https://www.activebiotech.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 8
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Ms. Helen Tuvesson Ph.D. | President & CEO | 4,04M | N/D | 1962 |
Mr. Hans Kolam | Chief Financial Officer | N/D | N/D | 1951 |
Dr. Erik Vahtola | Chief Medical Officer | N/D | N/D | 1976 |
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that has completed phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
L'ISS Governance QualityScore di Active Biotech AB (publ) al 1 maggio 2024 è 10. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 10; diritti degli azionisti: 1; retribuzione: 10.